Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522211 | 0.98 | PROKR2 (0.56) | PROKR2KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3516858 | 0.98 | PROKR2 (0.56) | PROKR2KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3518764 | 0.98 | PROKR2 (0.53) | PROKR2KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3518537 | 0.94 | PROKR2 (0.52) | PROKR2KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3516521 | 0.91 | PROKR2 (0.54) | PROKR2KMT2AALDH1A1KDM4EGRN | |
| SCHEMBL3520053 | 0.88 | PROKR2 (0.57) | PROKR2KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL3522275 | 0.84 | PROKR2 (0.58) | PROKR2KMT2AALDH1A1KDM4EGRN | |
| SCHEMBL3518564 | 0.84 | PROKR2 (0.61) | PROKR2KMT2AALDH1A1KDM4EGRN | |
| SCHEMBL3522266 | 0.84 | PROKR2 (0.55) | PROKR2KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL3517887 | 0.84 | PROKR2 (0.60) | PROKR2KMT2AALDH1A1KDM4EGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959959-B1 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-04-10 | — | — | EP | claimed |
| US-7855201-B2 | Morpholine carboxamide prokineticin receptor antagonists | Merck Sharp & Dohme. Corp. (US) | 2010-12-21 | — | — | US | claimed |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | claimed |
| EP-1959959-B1 | MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-04-10 | — | — | EP | disclosed |
| US-7855201-B2 | Morpholine carboxamide prokineticin receptor antagonists | Merck Sharp & Dohme. Corp. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855201-B2 | Morpholine carboxamide prokineticin receptor antagonists | Merck Sharp & Dohme. Corp. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306076-A1 | Morpholine Carboxamide Prokineticin Receptor Antagonists | PROKR2, PROKR1, NTSR2 | PROKR2 1/4885KMT2A 2847/4885ALDH1A1 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.